Mesothelioma clinical trials

The registry lists 305 studies for Mesothelioma across more than 10 countries. 61 are recruiting or about to start. 110 of them are mainly about Mesothelioma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its narrower condition Mesothelioma, Malignant too: 585 studies, 112 open.

Get an email when these change. Save the Mesothelioma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 126
Terminated: 59
Recruiting: 48
Active, not recruiting: 21
Status unknown: 21
Withdrawn: 12

Phase

Phase 1: 131
Phase 2: 126
Phase 3: 16
Early Phase 1: 6
Phase 4: 4

Where

United States: 188
United Kingdom: 36
France: 29
Italy: 28
Canada: 25
Spain: 22

Who runs them

National Cancer Institute (NCI) (23) · Memorial Sloan Kettering Cancer Center (8) · University of Chicago (7) · Eli Lilly and Company (6) · Novartis Pharmaceuticals (6) · Mayo Clinic (5) · M.D. Anderson Cancer Center (5) · Dana-Farber Cancer Institute (5)

What is being tested here

Drugs under test in Mesothelioma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Fluorine F 18 FAPI-74	2	0	2
Navlimetostat	2	0	2
Pemetrexed	1	2	15
Cisplatin	1	0	9
Carboplatin	1	0	6
Durvalumab	1	1	5
Olaparib	1	0	3
Tremelimumab	1	0	3
Magnesium Sulfate	1	0	2
Iparomlimab	1	0	1

Drug classes tested here Immune checkpoint inhibitors 3 open · Antimetabolites 2 open · Tyrosine kinase inhibitors (TKIs) 1 open · PARP inhibitors 1 open · Angiogenesis inhibitors 7

Coming up

3phase 3 studies under way

23studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jul 2027Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) · Phase 3 · Gruppo Oncologico Italiano di Ricerca Clinica
Nov 2026Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU · Brigham and Women's Hospital
Dec 2026A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors · HiFiBiO Therapeutics
Dec 2026Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma · Alliance for Clinical Trials in Oncology
Jan 2027A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors · Novartis Pharmaceuticals
Mar 2027A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers · Nuvectis Pharma, Inc.
Mar 2027Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. · NeoTX Therapeutics Ltd.
Mar 2027Exercise to Boost Immunity in Advanced Cancer · Sheffield Teaching Hospitals NHS Foundation Trust
Mar 2027Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma · Beijing Biotech
Apr 2027A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection · University Health Network, Toronto

Who these studies take

Of the 48 Mesothelioma studies recruiting now, 33 (69%) set no upper age limit and 4 (8%) stop at 75 or younger. 7 (15%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (8%) take healthy volunteers.

Recruiting studies that take each age, of 48
Age	Women	Men
10	6 (13%)	6 (13%)
18	45 (94%)	45 (94%)
30	46 (96%)	46 (96%)
40	46 (96%)	46 (96%)
50	46 (96%)	46 (96%)
65	46 (96%)	46 (96%)
75	46 (96%)	46 (96%)
85	43 (90%)	43 (90%)

Across all 305 studies, recruiting or not: 6% stop at 75 or younger and 1% at 65; 7% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Mesothelioma studies take

Of 42 phase 1 interventional studies under Mesothelioma, half reached primary completion within 45 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	45 mo29–63 · 42 studies	—	—
Phase 2	43 mo25–67 · 36 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 305. Browse all 305 → or search them.